Pfizer will stop the development of its twice-daily weight loss pill due to adverse side effects.
Share:
More In Business
Inside The Hidden Risks of Trump’s Housing Plan
Peachtree Group CEO Greg Friedman unpacks what a ban on institutional homebuyers could mean for affordability.
Discover The Minerals Powering America’s Tech Boom
Rita Adiani, CEO of Titan Mining, explains why graphite, zinc, and germanium are becoming vital to U.S. industry and security.
Inside Aeva's New Deal with Nvidia
Aeva CEO Soroush Salehian breaks down what the NVIDIA partnership signals for autonomous vehicles and the future of automation.
Inside Goodwill’s Retail Reinvention: Why People Can't Stop Thrifting
David Eagles, COO of Goodwill Industries International, explains how resale, culture shifts, and economics are fueling a secondhand boom.
Your 2026 Money Reset Starts Now
Personal finance reporter Oyin Adedoyin of The Wall Street Journal breaks down the smartest moves to reset savings, debt, and spending.
A Housing Fix or a Political Play? Trump Targets Institutional Buyers
Jeff Ostrowski, Housing Market Analyst at Bankrate, analyzes whether banning corporate buyers would help affordability or worsen supply shortages.
Big Business This Week: Will pressure on Fed chair Powell backfire?
The last 12 months have seen an extraordinary change in the way the U.S. economy works. Some analysts say that hasn’t been working out very well.
Oil Under U.S. Control? Breaking Down the Maduro Capture and Market Impacts
The U.S. is asserting control over Venezuelan oil after capturing President Maduro. Energy reporter Ben Geman of Axios breaks down what it means for markets and
From Stigma to Strategy: The Next Chapter for U.S. Cannabis Investing
Renewed investor interest and possible federal reforms may mark a turning point for U.S. cannabis. AdvisorShares’ Dan Ahrens explains what’s next.
